in Sode et al CMAJ 2013 doi: 10.1503/cmaj.121636.
In the Abstract you state that “two patients during their course of Rivaroxaban presented severe hematoma”, but in Table 1 it appears that the two hematomas occurred in the enoxaparin group? Please clarify.